Related Experiment Video
Updated: Dec 31, 2025
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
2.1K
[SMARCA4-deficient thoracic tumors: A new entity].
Elise Decroix1, Karen Leroy2, Marie Wislez3
1Cordeliers Research Center, « Immune Control and Escape », unité Inserm UMRS 1138, Paris, France; AP-HP, Université Paris Descartes, hôpital Cochin, département de pathologie, service d'anatomie pathologique, HUPC, 27, rue du faubourg Saint-Jacques, 74014 Paris, France.
Bulletin Du Cancer
|January 10, 2020
Summary
SWI/SNF complex alterations are linked to thoracic tumors like SMARCA4-deficient lung cancer and sarcoma. These tumors share clinical traits, but treatment options remain limited, with immunotherapy showing promise.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The SWI/SNF complex plays a crucial role in chromatin remodeling and acts as a tumor suppressor.
- Alterations in the SWI/SNF complex are observed in various cancers, including specific thoracic tumors.
- SMARCA4-deficient non-small cell lung carcinoma and SMARCA4-deficient sarcoma represent distinct thoracic malignancies associated with SWI/SNF complex alterations.
Purpose of the Study:
- To investigate the tumor suppressor role of the SWI/SNF complex.
- To characterize SMARCA4-deficient thoracic tumors, including their clinical and pathological features.
- To explore potential therapeutic strategies for these rare malignancies.
Main Methods:
- Review of existing studies on SWI/SNF complex alterations in cancer.
- Comparative analysis of clinical and morphological features of SMARCA4-deficient lung carcinoma and sarcoma.
- Evaluation of current and potential treatment modalities.
Main Results:
- SMARCA4-deficient thoracic tumors exhibit common features like intrathoracic localization, smoking history, male predominance, and poor prognosis.
- Histological differentiation between these tumor types can be challenging, suggesting a potential spectrum.
- Targeted therapies are limited due to lack of common driver mutations, but immunotherapy shows efficacy in some cases.
Conclusions:
- SMARCA4-deficient thoracic tumors represent a challenging group of malignancies with overlapping features.
- Further research is needed to clarify their exact relationship and establish standardized therapeutic protocols.
- Immunotherapy and potentially EZH2 inhibitors offer promising avenues for treatment in SMARCA4-deficient thoracic tumors.
